Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 153 No. 9 (2023)

Inappropriate proton-pump inhibitor prescribing in primary care – an observational study with quality circles

  • Renata Vidonscky Lüthold
  • Nicole Christin Henz
  • Connor Fuhrer
  • Andrea Häner
  • Michael Schenk
  • Katharina Tabea Jungo
  • Sven Streit
DOI
https://doi.org/10.57187/smw.2023.40119
Cite this as:
Swiss Med Wkly. 2023;153:40119
Published
21.09.2023

Summary

INTRODUCTION: Proton-pump inhibitors (PPIs) should be deprescribed when an indication is lacking or the dose is too high. Academic and media reports have tried to raise awareness and thereby reduce the inappropriate prescribing of PPIs. However, pharmacoepidemiologic studies have shown an unchanged frequency of such inappropriate prescribing over time. Little is known about whether or how general practitioners (GPs) adapt their prescribing practices once their awareness of inappropriate PPI prescribing has been raised.

OBJECTIVE: We aimed to investigate the prevalence of potentially inappropriate PPI prescribing (too high dose or no indication) in a consecutive sample of patients in Swiss primary care settings. Our goal was then to evaluate how GPs managed the patients with potentially inappropriate PPI prescribing over 12 months after flagging these patients.

METHODS: In this observational study, 11 GPs from the canton of Bern in Switzerland used their medical records to identify 20 patients who had been prescribed a PPI for ≥8 weeks and flagged potentially inappropriate PPI prescribing in their records. After 12 months, we asked the same GPs whether the PPI prescriptions of those patients had changed and, if so, how.

RESULTS: Of 1,376 patients consecutively screened, 206 (15%) had been prescribed a PPI for ≥8 weeks. Of these 206 patients, 85 (41%) had a potentially inappropriate PPI prescription. Of these 85 patients, 55 (65%) had no indication for PPI, and 30 (35%) had a too-high dose. After one year, only 29 (35%) of the 84 flagged potentially inappropriate PPIs were stopped or reduced. The most frequently mentioned reasons that deprescribing was not possible were a lack of discussion with the patient (no contact or no time), the presence of symptoms requiring the PPI, or the unwillingness of the patient to deprescribe.

CONCLUSION: In the Swiss primary care setting, the rate of potentially inappropriate PPI prescribing is high. Having GPs flag potentially inappropriate PPI prescribing did not result in PPI deprescribing in most patients over 12 months. Our findings suggest that more personalised and targeted interventions are necessary to successfully implement the deprescribing of potentially inappropriate PPIs. We see the need to co-design interventions with patients and providers and test behavioural change techniques to enable the deprescribing of inappropriate PPIs.

References

  1. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. British Medical Journal Publishing Group; 2008. pp. 2–3. DOI: https://doi.org/10.1136/bmj.39406.449456.BE
  2. Rane PP, Guha S, Chatterjee S, Aparasu RR. Prevalence and predictors of non-evidence based proton pump inhibitor use among elderly nursing home residents in the US. Res Social Adm Pharm. 2017;13(2):358–63. 10.1016/j.sapharm.2016.02.012 DOI: https://doi.org/10.1016/j.sapharm.2016.02.012
  3. Rückert-Eheberg IM, Nolde M, Ahn N, Tauscher M, Gerlach R, Güntner F, et al. Who gets prescriptions for proton pump inhibitors and why? A drug-utilization study with claims data in Bavaria, Germany, 2010-2018. Eur J Clin Pharmacol. 2022 Apr;78(4):657–67. 10.1007/s00228-021-03257-z DOI: https://doi.org/10.1007/s00228-021-03257-z
  4. Muheim L, Signorell A, Markun S, Chmiel C, Neuner-Jehle S, Blozik E, et al. Potentially inappropriate proton-pump inhibitor prescription in the general population: a claims-based retrospective time trend analysis. Therap Adv Gastroenterol. 2021 Apr;14:1756284821998928. 10.1177/1756284821998928 DOI: https://doi.org/10.1177/1756284821998928
  5. Savarino V, Dulbecco P, de Bortoli N, Ottonello A, Savarino E. The appropriate use of proton pump inhibitors (PPIs): need for a reappraisal. Eur J Intern Med. 2017 Jan;37:19–24. 10.1016/j.ejim.2016.10.007 DOI: https://doi.org/10.1016/j.ejim.2016.10.007
  6. Savarino V, Marabotto E, Zentilin P, Furnari M, Bodini G, De Maria C, et al. Proton pump inhibitors: use and misuse in the clinical setting. Expert Rev Clin Pharmacol. 2018 Nov;11(11):1123–34. 10.1080/17512433.2018.1531703 DOI: https://doi.org/10.1080/17512433.2018.1531703
  7. Heidelbaugh JJ, Kim AH, Chang R, Walker PC. Overutilization of proton-pump inhibitors: what the clinician needs to know. Therap Adv Gastroenterol. 2012 Jul;5(4):219–32. 10.1177/1756283X12437358 DOI: https://doi.org/10.1177/1756283X12437358
  8. Abraham NS. Proton pump inhibitors: potential adverse effects. Curr Opin Gastroenterol. 2012 Nov;28(6):615–20. 10.1097/MOG.0b013e328358d5b9 DOI: https://doi.org/10.1097/MOG.0b013e328358d5b9
  9. Deshpande A, Pant C, Pasupuleti V, Rolston DD, Jain A, Deshpande N, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol. 2012 Mar;10(3):225–33. 10.1016/j.cgh.2011.09.030 DOI: https://doi.org/10.1016/j.cgh.2011.09.030
  10. Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Official journal of the American College of Gastroenterology| ACG. 2011;106(7):1209-18. 10.1038/ajg.2011.113 DOI: https://doi.org/10.1038/ajg.2011.113
  11. Song H, Zhu J, Lu D. Long‐term proton pump inhibitor (PPI) use and the development of gastric pre‐malignant lesions. Cochrane Database Syst Rev. 2014(12). DOI: https://doi.org/10.1002/14651858.CD010623.pub2
  12. Reimer C. Safety of long-term PPI therapy. Best Pract Res Clin Gastroenterol. 2013 Jun;27(3):443–54. 10.1016/j.bpg.2013.06.001 DOI: https://doi.org/10.1016/j.bpg.2013.06.001
  13. Jaynes M, Kumar AB. The risks of long-term use of proton pump inhibitors: a critical review. Ther Adv Drug Saf. 2018 Nov;10:2042098618809927. DOI: https://doi.org/10.1177/2042098618809927
  14. Ladd AM, Panagopoulos G, Cohen J, Mar N, Graham R. Potential costs of inappropriate use of proton pump inhibitors. Am J Med Sci. 2014 Jun;347(6):446–51. 10.1097/MAJ.0b013e31829f87d5 DOI: https://doi.org/10.1097/MAJ.0b013e31829f87d5
  15. Ahrens D, Chenot JF, Behrens G, Grimmsmann T, Kochen MM. Appropriateness of treatment recommendations for PPI in hospital discharge letters. Eur J Clin Pharmacol. 2010 Dec;66(12):1265–71. 10.1007/s00228-010-0871-9 DOI: https://doi.org/10.1007/s00228-010-0871-9
  16. Perren A, Donghi D, Marone C, Cerutti B. Economic burden of unjustified medications at hospital discharge. Swiss Med Wkly. 2009 Jul;139(29-30):430–5. DOI: https://doi.org/10.4414/smw.2009.12624
  17. Hamzat H, Sun H, Ford JC, Macleod J, Soiza RL, Mangoni AA. Inappropriate prescribing of proton pump inhibitors in older patients: effects of an educational strategy. Drugs Aging. 2012 Aug;29(8):681–90. 10.1007/BF03262283 DOI: https://doi.org/10.1007/BF03262283
  18. Chia CT, Lim WP, Vu CK. Inappropriate use of proton pump inhibitors in a local setting. Singapore Med J. 2014 Jul;55(7):363–6. 10.11622/smedj.2014087 DOI: https://doi.org/10.11622/smedj.2014087
  19. Batuwitage BT, Kingham JG, Morgan NE, Bartlett RL. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J. 2007 Jan;83(975):66–8. 10.1136/pgmj.2006.051151 DOI: https://doi.org/10.1136/pgmj.2006.051151
  20. Daniels B, Pearson SA, Buckley NA, Bruno C, Zoega H. Long-term use of proton-pump inhibitors: whole-of-population patterns in Australia 2013-2016. Therap Adv Gastroenterol. 2020 Mar;13:1756284820913743. 10.1177/1756284820913743 DOI: https://doi.org/10.1177/1756284820913743
  21. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009 Mar;301(9):937–44. 10.1001/jama.2009.261 DOI: https://doi.org/10.1001/jama.2009.261
  22. Scarpignato C, Gatta L, Zullo A, Blandizzi C; SIF-AIGO-FIMMG Group; Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016 Nov;14(1):179. 10.1186/s12916-016-0718-z DOI: https://doi.org/10.1186/s12916-016-0718-z
  23. Yadlapati R, Kahrilas PJ. When is proton pump inhibitor use appropriate? BMC Med. 2017 Feb;15(1):36. 10.1186/s12916-017-0804-x DOI: https://doi.org/10.1186/s12916-017-0804-x
  24. Farrell B, Pottie K, Thompson W, Boghossian T, Pizzola L, Rashid FJ, et al. Deprescribing proton pump inhibitors: evidence-based clinical practice guideline. Can Fam Physician. 2017 May;63(5):354–64.
  25. Reeve E, Gnjidic D, Long J, Hilmer S. A systematic review of the emerging definition of ‘deprescribing’ with network analysis: implications for future research and clinical practice. Br J Clin Pharmacol. 2015 Dec;80(6):1254–68. 10.1111/bcp.12732 DOI: https://doi.org/10.1111/bcp.12732
  26. Farrell B, Lass E, Moayyedi P, Ward D, Thompson W. Reduce unnecessary use of proton pump inhibitors. BMJ. 2022 Oct;379:e069211. 10.1136/bmj-2021-069211 DOI: https://doi.org/10.1136/bmj-2021-069211
  27. Mazer-Amirshahi M, Mullins PM, van den Anker J, Meltzer A, Pines JM. Rising rates of proton pump inhibitor prescribing in US emergency departments. Am J Emerg Med. 2014 Jun;32(6):618–22. 10.1016/j.ajem.2014.03.019 DOI: https://doi.org/10.1016/j.ajem.2014.03.019
  28. Haastrup P, Paulsen MS, Zwisler JE, Begtrup LM, Hansen JM, Rasmussen S, et al. Rapidly increasing prescribing of proton pump inhibitors in primary care despite interventions: a nationwide observational study. Eur J Gen Pract. 2014 Dec;20(4):290–3. 10.3109/13814788.2014.905535 DOI: https://doi.org/10.3109/13814788.2014.905535
  29. Hollingworth S, Duncan EL, Martin JH. Marked increase in proton pump inhibitors use in Australia. Pharmacoepidemiol Drug Saf. 2010 Oct;19(10):1019–24. 10.1002/pds.1969 DOI: https://doi.org/10.1002/pds.1969
  30. Smarter medicine - Choosing Wisely Switzerland. Top-5-Listen – Ambulante Allgemeine Innere Medizin. Available from: https://www.smartermedicine.ch/. Accessed in 07 May 2023. DOI: https://doi.org/10.4414/saez.2023.22050
  31. SRF. Die beliebten Magensäure-Bremser sind nicht ohne. SRF; 2016. Available from: https://www.srf.ch/wissen/gesundheit/die-beliebten-magensaeure-bremser-sind-nicht-ohne. Accessed in 25 May 2023.
  32. Rohrbasser A, Kirk UB, Arvidsson E. Use of quality circles for primary care providers in 24 European countries: an online survey of European Society for Quality and Safety in family practice delegates. Scand J Prim Health Care. 2019 Sep;37(3):302–11. 10.1080/02813432.2019.1639902 DOI: https://doi.org/10.1080/02813432.2019.1639902
  33. World Health Organization. Defined Daily Dose (DDD) Index. Available on https://www.whocc.no/atc_ddd_index/?code=A02BC. Accessed 2023 May 17.
  34. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011 May;46(3):399–424. 10.1080/00273171.2011.568786 DOI: https://doi.org/10.1080/00273171.2011.568786
  35. Hopewell S, Hirst A, Collins GS, Mallett S, Yu LM, Altman DG. Reporting of participant flow diagrams in published reports of randomized trials. Trials. 2011 Dec;12(1):253. 10.1186/1745-6215-12-253 DOI: https://doi.org/10.1186/1745-6215-12-253
  36. Liu Y, Zhu X, Li R, Zhang J, Zhang F. Proton pump inhibitor utilisation and potentially inappropriate prescribing analysis: insights from a single-centred retrospective study. BMJ Open. 2020 Nov;10(11):e040473. 10.1136/bmjopen-2020-040473 DOI: https://doi.org/10.1136/bmjopen-2020-040473
  37. Choudhry MN, Soran H, Ziglam HM. Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease. QJM. 2008 Jun;101(6):445–8. 10.1093/qjmed/hcn035 DOI: https://doi.org/10.1093/qjmed/hcn035
  38. Brandhagen DJ, Pheley AM, Onstad GR, Freeman ML, Lurie N. Omeprazole use at an urban county teaching hospital. J Gen Intern Med. 1995 Sep;10(9):513–5. 10.1007/BF02602404 DOI: https://doi.org/10.1007/BF02602404
  39. Giannini EG, Crespi M, Djahandideh A, Demarzo MG, Moscatelli A, Bodini G, et al. Appropriateness of proton pump inhibitors treatment in clinical practice: prospective evaluation in outpatients and perspective assessment of drug optimisation. Dig Liver Dis. 2020 Aug;52(8):862–8. 10.1016/j.dld.2020.05.005 DOI: https://doi.org/10.1016/j.dld.2020.05.005
  40. Odenthal DR, Philbrick AM, Harris IM. Successful deprescribing of unnecessary proton pump inhibitors in a primary care clinic. J Am Pharm Assoc (2003). 2020;60(1):100-4. DOI: https://doi.org/10.1016/j.japh.2019.08.012
  41. Nowbahari E, Bigot A, Maillot F, Antier D, Foucault-Fruchard L. Reassessment of inappropriate prescriptions of proton pump inhibitors in elderly in-patients: it’s time to take action. Ann Pharm Fr. 2020 Mar;78(2):150–7. 10.1016/j.pharma.2020.01.001 DOI: https://doi.org/10.1016/j.pharma.2020.01.001
  42. Hálfdánarson ÓÖ, Pottegård A, Björnsson ES, Lund SH, Ogmundsdottir MH, Steingrímsson E, et al. Proton-pump inhibitors among adults: a nationwide drug-utilization study. Therap Adv Gastroenterol. 2018 May;11:1756284818777943. 10.1177/1756284818777943 DOI: https://doi.org/10.1177/1756284818777943
  43. Dharmarajan TS. The Use and Misuse of Proton Pump Inhibitors: An Opportunity for Deprescribing. J Am Med Dir Assoc. 2021 Jan;22(1):15–22. 10.1016/j.jamda.2020.09.046 DOI: https://doi.org/10.1016/j.jamda.2020.09.046
  44. Munson JC, Wahl PM, Daniel G, Kimmel SE, Hennessy S. Factors associated with the initiation of proton pump inhibitors in corticosteroid users. Pharmacoepidemiol Drug Saf. 2012 Apr;21(4):366–74. 10.1002/pds.2350 DOI: https://doi.org/10.1002/pds.2350
  45. Lassalle M, Le Tri T, Bardou M, Biour M, Kirchgesner J, Rouby F, et al. Use of proton pump inhibitors in adults in France: a nationwide drug utilization study. Eur J Clin Pharmacol. 2020 Mar;76(3):449–57. 10.1007/s00228-019-02810-1 DOI: https://doi.org/10.1007/s00228-019-02810-1
  46. Parente F, Cucino C, Gallus S, Bargiggia S, Greco S, Pastore L, et al. Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: a 1-month survey. Aliment Pharmacol Ther. 2003 Jun;17(12):1503–6. 10.1046/j.1365-2036.2003.01600.x DOI: https://doi.org/10.1046/j.1365-2036.2003.01600.x
  47. Ahrens D, Behrens G, Himmel W, Kochen MM, Chenot JF. Appropriateness of proton pump inhibitor recommendations at hospital discharge and continuation in primary care. Int J Clin Pract. 2012 Aug;66(8):767–73. 10.1111/j.1742-1241.2012.02973.x DOI: https://doi.org/10.1111/j.1742-1241.2012.02973.x
  48. Achterhof AB, Rozsnyai Z, Reeve E, Jungo KT, Floriani C, Poortvliet RK, et al. Potentially inappropriate medication and attitudes of older adults towards deprescribing. PLoS One. 2020 Oct;15(10):e0240463. 10.1371/journal.pone.0240463 DOI: https://doi.org/10.1371/journal.pone.0240463
  49. Nyborg G, Brekke M, Straand J, Gjelstad S, Romøren M. Potentially inappropriate medication use in nursing homes: an observational study using the NORGEP-NH criteria. BMC Geriatr. 2017 Sep;17(1):220. 10.1186/s12877-017-0608-z DOI: https://doi.org/10.1186/s12877-017-0608-z
  50. Fromm MF, Maas R, Tümena T, Gaßmann KG. Potentially inappropriate medications in a large cohort of patients in geriatric units: association with clinical and functional characteristics. Eur J Clin Pharmacol. 2013 Apr;69(4):975–84. 10.1007/s00228-012-1425-0 DOI: https://doi.org/10.1007/s00228-012-1425-0
  51. Pottegård A, Broe A, Hallas J, de Muckadell OB, Lassen AT, Lødrup AB. Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study. Therap Adv Gastroenterol. 2016 Sep;9(5):671–8. 10.1177/1756283X16650156 DOI: https://doi.org/10.1177/1756283X16650156
  52. Cahir C, Fahey T, Teeling M, Teljeur C, Feely J, Bennett K. Potentially inappropriate prescribing and cost outcomes for older people: a national population study. Br J Clin Pharmacol. 2010 May;69(5):543–52. 10.1111/j.1365-2125.2010.03628.x DOI: https://doi.org/10.1111/j.1365-2125.2010.03628.x
  53. Duncan P, Duerden M, Payne RA. Deprescribing: a primary care perspective. Eur J Hosp Pharm Sci Pract. 2017 Jan;24(1):37–42. 10.1136/ejhpharm-2016-000967 DOI: https://doi.org/10.1136/ejhpharm-2016-000967
  54. Isenor JE, Bai I, Cormier R, Helwig M, Reeve E, Whelan AM, et al. Deprescribing interventions in primary health care mapped to the Behaviour Change Wheel: A scoping review. Res Social Adm Pharm. 2021 Jul;17(7):1229–41. 10.1016/j.sapharm.2020.09.005 DOI: https://doi.org/10.1016/j.sapharm.2020.09.005
  55. Hansen CR, O’Mahony D, Kearney PM, Sahm LJ, Cullinan S, Huibers CJ, et al. Identification of behaviour change techniques in deprescribing interventions: a systematic review and meta-analysis. Br J Clin Pharmacol. 2018 Dec;84(12):2716–28. 10.1111/bcp.13742 DOI: https://doi.org/10.1111/bcp.13742

Most read articles by the same author(s)